Screener
Sarepta Therapeutics, Inc. SRPT Business Segments — Roche Collaboration Reimbursement
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Sarepta Therapeutics, Inc. in its filing.
Tagged under the XBRL concept srpt:RocheCollaborationReimbursement.
The source filing: Sarepta Therapeutics, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:01 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-335003
| Line item | For the Three Months Ended June 30, 2026 | For the Three Months Ended June 30, 2025 | For the Six Months Ended June 30, 2026 | For the Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Facility- and technology-related expenses (excluding depreciation and amortization) | 23,890 | 28,580 | 46,832 | 56,237 |
| Research and development- other (excluding non-cash items) (1) | 19,847 | 31,843 | 38,518 | 60,314 |
| Selling, general and administrative- other (excluding non-cash items) (2) | 42,462 | 56,322 | 82,655 | 107,464 |
| Roche collaboration reimbursement | (7,169) | (25,689) | (15,358) | (54,170) |
| Other segment items (3) | (709) | (1,314) | (2,515) | (3,223) |
| Loss (gain) on strategic investments | 448 | (36,721) | 2,160 | 54,007 |
| Interest expense | 21,508 | 5,228 | 43,221 | 9,731 |
| Interest income | (6,207) | (5,254) | (12,567) | (15,444) |
Item 1. Financial Statements
FAQ
- What is Sarepta Therapeutics, Inc.'s business segments — roche collaboration reimbursement?
- Sarepta Therapeutics, Inc. (SRPT) reported business segments — roche collaboration reimbursement of -$7.17M in Q2 2026.
- How has Sarepta Therapeutics, Inc.'s business segments — roche collaboration reimbursement changed year-over-year?
- Sarepta Therapeutics, Inc.'s business segments — roche collaboration reimbursement increased by 72.1% year-over-year, from -$25.69M to -$7.17M.
- What is the long-term trend for Sarepta Therapeutics, Inc.'s business segments — roche collaboration reimbursement?
- Over 3 years (2022 to 2025), Sarepta Therapeutics, Inc.'s business segments — roche collaboration reimbursement has grown at a -10.4% compound annual growth rate (CAGR), from -$117.81M to -$84.73M.
- What does business segments — roche collaboration reimbursement mean?
- Tracks the financial inflows or cost-sharing reimbursements received from a strategic partnership with Roche. This metric indicates the impact of collaborative agreements on the segment's net operating costs.
Ask your AI about Sarepta Therapeutics, Inc.'s business segments — roche collaboration reimbursement.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude